Skip to content

FATE THERAPEUTICS, INC.

FATE

CIK 0001434316

← back to feed
Revenue (TTM)
$6.58M
−51.2% YoY Q1 May 2026
Net Income (TTM)
−$135.15M
+26.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.14
+29.9% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-2,219.9%
Q1 May 2026
Net Margin
-2,055.3%
Q1 May 2026
Free Cash Flow (TTM)
−$131.57M
Q1 May 2026
Cash
$39.57M
Q1 May 2026
Total Debt
$23.4M
Q1 May 2026
Shares Outstanding
116.56M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings